As of the end of the quarter Teacher Retirement System Of Texas had acquired 19 shares growing its stake by 0.1%.
Geron Corporation (NASDAQ GERN) traded down 15.47% during trading on Tuesday, hitting $2.24.
Several other equities analysts have also weighed in on the stock. Geode Capital Management LLC boosted its stake in shares of Geron Corporation by 11.0% in the first quarter. NY now owns 112,793 shares of the biopharmaceutical company's stock worth $233,000 after buying an additional 732 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Geron Corporation during the first quarter valued at about $820,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of Geron Corporation by 31.0% in the first quarter. Earnings surprises can have a huge impact on a company's stock price. Bank of America Corp DE increased its position in shares of Geron Corporation by 26.5% in the first quarter. Vanguard Group Inc. now owns 7,112,183 shares of the biopharmaceutical company's stock valued at $16,145,000 after buying an additional 502,485 shares in the last quarter.
Large investors have recently modified their holdings of the company. The value of the investment in Geron Corporation decreased from $55,000 to $43,000 decreasing 21.8% for the reporting period. The stock touched 52-week High of $3.15 on 05/16/17 and 52-week Low of $1.81 on 11/03/16. The stock's 50-day moving average price is $2.68 and its 200-day moving average price is $2.47. It has a market cap of $346.29 Million.
Shares of Geron Corporation (NASDAQ:GERN) now have an Average Brokerage Recommendation of 2, number of Recs in ABR is 2 while industry rank of the company by ABR is out of 265. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01, Briefing.com reports.
While having a peek at profitability ratios Geron Corporation (NASDAQ:GERN) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
3 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 0.27 million while high and low sale targets are estimated at 0.62 million. The business's revenue for the quarter was down 28.0% compared to the same quarter previous year. In contrast to the year ago quarter EPS was at 0.12.
ILLEGAL ACTIVITY NOTICE: This report was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of worldwide copyright & trademark legislation. The original version of this article can be read at https://www.chaffeybreeze.com/2017/08/02/fbr-co-reaffirms-buy-rating-for-geron-corporation-gern-updated-updated-updated.html.
Oppenheimer added GERN to its research portfolio giving it an initial rating of "Outperform" and establishing a price target of $5.50.
Taking a broader look at the analyst consensus, according to 2 analysts Geron Corporation (NASDAQ:GERN)'s price will reach at $3.75 during 52 weeks. Stifel Nicolaus restated a "hold" rating and set a $2.50 target price on shares of Geron Corporation in a research report on Wednesday, April 12th. Piper Jaffray Companies restated an "overweight" rating and set a $5.00 price objective on shares of Geron Corporation in a research note on Wednesday, April 12th.
On June 12 the company was upgraded from "Hold" to "Buy" with a current price target of $4.25 by analysts at MLV & Co. The stock's average target of $5.88 is 168.49% above today's ($2.19) share price.